However, despite current guidelines that strongly recommend the use of GLP-1 RAs in patients with T2D who already have or are at high risk for CVD [8-10], most patients who are eligible for these treatments are not receiving them. The gene discussed is GLP1R; the disease is type 2 diabetes mellitus.